胃がん治療の市場規模、シェア、動向分析レポート：治療タイプ別、疾患適応症別、投与経路別、薬剤クラス別、地域別、セグメント予測、2025年～2030年

胃がん治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の胃がん治療市場規模は2030年までに111億9,000万米ドルに達すると推定され、2025年から2030年にかけて12.5%のCAGRで成長する見込みです。

免疫療法や分子標的治療の普及と新薬の上市が成長を促進すると予想されています。

Globocanによると、2020年の胃がん罹患率は約110万人で、2030年には142万人に増加すると予想されています。疾患の分子的基礎に関する知識が増えるにつれ、開発され市場に投入される標的薬や免疫療法薬の数が増加しています。ハーセプチンなどのHER-2標的薬は、2010年以来市場で入手可能です。また、VEGFを標的とするモノクローナル抗体であるサイラムザも2014年から発売されています。EGFRやPD-1を標的とした薬剤や免疫療法は現在、胃がんの治療薬として開発されています。

臨床パイプラインにある薬剤の承認とその後の上市も、胃がん治療市場を牽引すると予想されます。例えば、2021年3月、NMPAはEli LillyとInnovent Biologicsの医薬品であるPD-1阻害薬Sintilimabを胃がんまたは胃食道接合部腺がんの治療薬として中国で承認しました。さらに2020年5月、米国FDAは胃がん治療薬としてエンヘルトゥを希少疾病用医薬品に指定しました。その後、2021年1月に米国FDAはエンヘルツを進行性または転移性胃がんの治療薬として承認しました。

ハーセプチンなどの主要薬剤の特許切れとそれに続くバイオシミラーの発売は、胃がん治療市場の成長を抑制すると予想されます。さらに、高コストのために標的治療の採用が少ないことも、市場の成長を妨げる可能性があります。例えば、サイラムザは他の薬剤と比較して費用対効果が低いと考えられていました。英国では費用対効果が低いとしてNICEから却下されました。さらに、フランスでは、臨床的に関連性のある比較対象品と比較してその他の特典がないという理由で償還が却下されました。

胃がん治療市場レポート・ハイライト

• 標的療法が市場を独占し、2024年には39.6%のシェアを占めました。標的療法は、隣接する健康な組織への害を最小限に抑えながら、がん細胞を正確に標的とします。
• 胃がん/胃食道接合部が2024年の売上高シェア84.7%で市場をリードしました。
• 注射療法は、迅速な治療作用と化学療法や標的療法を血流に直接投与する有効性により、2024年に89.0%の最大売上シェアを占めました。
• VEGFR拮抗薬は、腫瘍の成長と転移に不可欠なプロセスである腫瘍の血管新生を阻害するという重要な役割により、2024年にかなりのシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 胃がん治療市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析

第4章 胃がん治療市場：治療タイプ別ビジネス分析

• 治療タイプの市場シェア、2024年および2030年
• 治療タイプセグメントダッシュボード
• 市場規模と予測および動向分析、治療タイプ別、2018～2030年
• 標準化学療法
• 標的療法
• 免疫療法

第5章 胃がん治療市場：疾患適応症別ビジネス分析

• 疾患適応症の市場シェア、2024年および2030年
• 疾患適応症セグメントダッシュボード
• 市場規模と予測および動向分析、疾患別、2018～2030年
• 胃がん・胃食道接合部がん
• 消化管間質腫瘍

第6章 胃がん治療市場：投与経路別ビジネス分析

• 投与経路の市場シェア、2024年および2030年
• 投与経路セグメントダッシュボード
• 市場規模と予測および動向分析、投与経路別、2018～2030年
• 経口
• 注射可能

第7章 胃がん治療市場：薬剤クラスのビジネス分析

• 薬物クラスの市場シェア、2024年および2030年
• 薬物クラスセグメントダッシュボード
• 市場規模と予測および動向分析、薬剤クラス別、2018～2030年
• PD-1/PD-L1阻害剤
• HER2拮抗薬
• VEGFR拮抗薬
• その他

第8章 胃がん治療市場：地域推定・動向分析

• 地域別の市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novartis AG
  • Pfizer Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • CELLTRION INC.
  • Samsung Bioepis
  • Bristol-Myers Squibb Company

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global stomach cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 4. Global stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 5. Global stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 6. Global stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 7. Global stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 8. North America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
• Table 9. North America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 10. North America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 11. North America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 12. North America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 13. U.S. stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 14. U.S. stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 15. U.S. stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 16. U.S. stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 17. Canada stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 18. Canada stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 19. Canada stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 20. Canada stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 21. Mexico stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 22. Mexico stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 23. Mexico stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 24. Mexico stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 25. Europe stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
• Table 26. Europe stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 27. Europe stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 28. Europe stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 29. Europe stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 30. UK stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 31. UK stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 32. UK stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 33. UK stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 34. Germany stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 35. Germany stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 36. Germany stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 37. Germany stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 38. France stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 39. France stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 40. France stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 41. France stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 42. Italy stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 43. Italy stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 44. Italy stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 45. Italy stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 46. Spain stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 47. Spain stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 48. Spain stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 49. Spain stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 50. Denmark stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 51. Denmark stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 52. Denmark stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 53. Denmark stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 54. Sweden stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 55. Sweden stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 56. Sweden stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 57. Sweden stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 58. Norway stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 59. Norway stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 60. Norway stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 61. Norway stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 62. Asia Pacific stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
• Table 63. Asia Pacific stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 64. Asia Pacific stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 65. Asia Pacific stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 66. Asia Pacific stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 67. China stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 68. China stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 69. China stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 70. China stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 71. Japan stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 72. Japan stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 73. Japan stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 74. Japan stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 75. India stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 76. India stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 77. India stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 78. India stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 79. Australia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 80. Australia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 81. Australia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 82. Australia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 83. South Korea stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 84. South Korea stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 85. South Korea stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 86. South Korea stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 87. Thailand stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 88. Thailand stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 89. Thailand stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 90. Thailand stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 91. Latin America stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
• Table 92. Latin America stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 93. Latin America stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 94. Latin America stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 95. Latin America stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 96. Brazil stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 97. Brazil stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 98. Brazil stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 99. Brazil stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 100. Argentina stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 101. Argentina stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 102. Argentina stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 103. Argentina stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 104. Middle East & Africa Stomach cancer treatment market, by country, 2018 - 2030 (USD Million)
• Table 105. Middle East & Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 106. Middle East & Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 107. Middle East & Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 108. Middle East & Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 109. South Africa stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 110. South Africa stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 111. South Africa stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 112. South Africa stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 113. Saudi Arabia stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 114. Saudi Arabia stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 115. Saudi Arabia stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 116. Saudi Arabia stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 117. UAE stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 118. UAE stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 119. UAE stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 120. UAE stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 121. Kuwait stomach cancer treatment market, by treatment type, 2018 - 2030 (USD Million)
• Table 122. Kuwait stomach cancer treatment market, by disease indication, 2018 - 2030 (USD Million)
• Table 123. Kuwait stomach cancer treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 124. Kuwait stomach cancer treatment market, by drug class, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Stomach cancer treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Treatment type and disease indication outlook (USD Million)
• Fig. 10 Route of administration and drug class outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Stomach cancer treatment market dynamics
• Fig. 13 Stomach cancer treatment market: Porter's five forces analysis
• Fig. 14 Stomach cancer treatment market: PESTLE analysis
• Fig. 15 Others market, 2018 - 2030 (USD Million)
• Fig. 16 Stomach cancer treatment market: Treatment type segment dashboard
• Fig. 17 Stomach cancer treatment market: Treatment type market share analysis, 2024 & 2030
• Fig. 18 Standard chemotherapy market, 2018 - 2030 (USD Million)
• Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
• Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
• Fig. 21 Stomach cancer treatment market: Disease indication segment dashboard
• Fig. 22 Stomach cancer treatment market: Disease indication market share analysis, 2024 & 2030
• Fig. 23 Gastric cancer/gastroesophageal junction cancer market, 2018 - 2030 (USD Million)
• Fig. 24 Gastrointestinal stromal tumors market, 2018 - 2030 (USD Million)
• Fig. 25 Stomach cancer treatment market: Route of administration segment dashboard
• Fig. 26 Stomach cancer treatment market: Route of administration market share analysis, 2024 & 2030
• Fig. 27 Oral market, 2018 - 2030 (USD Million)
• Fig. 28 Injectable market, 2018 - 2030 (USD Million)
• Fig. 29 Stomach cancer treatment market: Drug class segment dashboard
• Fig. 30 Stomach cancer treatment market: Drug class market share analysis, 2024 & 2030
• Fig. 31 PD-1/PD-L1 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 32 HER2 antagonists market, 2018 - 2030 (USD Million)
• Fig. 33 VEGFR antagonists market, 2018 - 2030 (USD Million)
• Fig. 34 Stomach cancer treatment market revenue, by region
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 Regional marketplace: Key takeaways
• Fig. 37 North America stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 38 U.S. country dynamics
• Fig. 39 U.S. stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 40 Canada country dynamics
• Fig. 41 Canada stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 42 Mexico country dynamics
• Fig. 43 Mexico stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 44 Europe stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 45 UK country dynamics
• Fig. 46 UK stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 47 Germany country dynamics
• Fig. 48 Germany stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 49 France country dynamics
• Fig. 50 France stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 51 Italy country dynamics
• Fig. 52 Italy stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 53 Spain country dynamics
• Fig. 54 Spain stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 55 Norway country dynamics
• Fig. 56 Norway stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 57 Sweden country dynamics
• Fig. 58 Sweden stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 59 Denmark country dynamics
• Fig. 60 Denmark stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 61 Asia Pacific stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 62 Japan country dynamics
• Fig. 63 Japan stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 64 China country dynamics
• Fig. 65 China stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 66 India country dynamics
• Fig. 67 India stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 68 Australia country dynamics
• Fig. 69 Australia stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 70 South Korea country dynamics
• Fig. 71 South Korea stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 72 Thailand country dynamics
• Fig. 73 Thailand stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 74 Latin America stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 75 Brazil country dynamics
• Fig. 76 Brazil stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 77 Argentina country dynamics
• Fig. 78 Argentina stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 79 MEA stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 80 South Africa country dynamics
• Fig. 81 South Africa stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 82 Saudi Arabia country dynamics
• Fig. 83 Saudi Arabia stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 84 UAE country dynamics
• Fig. 85 UAE stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 86 Kuwait country dynamics
• Fig. 87 Kuwait stomach cancer treatment market, 2018 - 2030 (USD Million)
• Fig. 88 Company categorization
• Fig. 89 Company market position analysis
• Fig. 90 Strategic framework

Stomach Cancer Treatment Market Growth & Trends:

The global stomach cancer treatment market size is estimated to reach USD 11.19 billion by 2030, registering to grow at a CAGR of 12.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics' drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights:

• Targeted therapy dominated the market and accounted for a share of 39.6% in 2024. Targeted therapy offers precision targeting cancer cells while minimizing harm to adjacent healthy tissues.
• Gastric cancer/gastroesophageal junction led the market with a revenue share of 84.7% in 2024, fueled by its considerable prevalence and associated mortality rates worldwide.
• Injectable treatment held the largest revenue share of 89.0% in 2024, aided by their rapid therapeutic action and effectiveness in administering chemotherapy and targeted therapies directly into the bloodstream.
• VEGFR antagonists held a substantial share in 2024 due to their critical role in inhibiting tumor angiogenesis, a vital process for tumor growth and metastasis.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment Type
  • 1.2.2. Disease Indication
  • 1.2.3. Route of Administration
  • 1.2.4. Drug Class
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Stomach Cancer Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Stomach Cancer Treatment Market: Treatment Type Business Analysis

• 4.1. Treatment Type Market Share, 2024 & 2030
• 4.2. Treatment Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Million)
• 4.4. Standard Chemotherapy
  • 4.4.1. Standard Chemotherapy Market, 2018 - 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)

Chapter 5. Stomach Cancer Treatment Market: Disease Indication Business Analysis

• 5.1. Disease Indication Market Share, 2024 & 2030
• 5.2. Disease Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
• 5.4. Gastric Cancer/Gastroesophageal Junction Cancer
  • 5.4.1. Gastric Cancer/Gastroesophageal Junction Cancer Market, 2018 - 2030 (USD Million)
• 5.5. Gastrointestinal Stromal Tumors
  • 5.5.1. Gastrointestinal Stromal Tumors Market, 2018 - 2030 (USD Million)

Chapter 6. Stomach Cancer Treatment Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. Stomach Cancer Treatment Market: Drug Class Business Analysis

• 7.1. Drug Class Market Share, 2024 & 2030
• 7.2. Drug Class Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 7.4. PD-1/PD-L1 Inhibitors
  • 7.4.1. PD-1/PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
• 7.5. HER2 Antagonists
  • 7.5.1. HER2 Antagonists Market, 2018 - 2030 (USD Million)
• 7.6. VEGFR Antagonists
  • 7.6.1. VEGFR Antagonists Market, 2018 - 2030 (USD Million)
• 7.7 Others
  • 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Stomach Cancer Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Stomach Cancer Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novartis AG
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Pfizer Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Mylan N.V.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. F. Hoffmann-La Roche Ltd
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Eli Lilly and Company
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Merck & Co., Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Teva Pharmaceutical Industries Ltd.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. CELLTRION INC.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Samsung Bioepis
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Bristol-Myers Squibb Company
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives